Short interest for Skillsoft gives investors a sense of the degree to which investors are betting on the decline of Skillsoft's stock. Short interest data is updated every two weeks.

Skillsoft Stock (NYSE:SKIL), Short Interest Report

Skillsoft

Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.

Aon - logo

News

Intraday Update

Markets

Movers

ACCD

ACMR

ACON

AILE

AIRE

ALSN

APPF

ARCB

ATXI

BACK

BDRX

CGEM

CSSE

DXCM

ELWS

EXPO

FCUV

FRGT

GOOG

GOOGL

ICLK

INTC

KNSL

KTOS

Kintara Therapeutics, Inc. - Common Stock

KTRA

Eaton Vance Massachusetts Municipal Income Trust

NIVF

NUWE

NWGL

ODFL

PCSA

PEGY

RERE

ROKU

SAIA

SBFM

SGBX

SKIL

SLCA

SNAP

TEAM

TNET

TVGN

VINC

WORX

ZVSA

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Penny Stocks

Small Cap

Trading Ideas

ACDC

ADXN

BENF

BNED

BSGM

CLDI

CSLR

CTNM

DFLI

DYNT

ERIC

ITCI

JAGX

KAVL

MCBC

MNSO

PACB

PALI

PRFX

PRSO

PRZO

RNAC

RVYL

SMXT

SPRC

SXTC

SYTA

TAOP

WISA

WFTC

Shares of  Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Man.Markets.Shutterstock

Equities

Large Cap

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Treasuries

Econ #s

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

IBKR

JBHT

NTRS

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Investors remain on edge as geopolitics continue to shape market trends, with Israel mulling a response to Iran while the U.S. and key allies explore further sanctions against Tehran.

Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What&#39;s Driving Markets Tuesday?

Skillsoft Corp

CryptoBlades

Skillful Craftsman Education Technology Limited - Ordinary Share

Skillful Craftsman Education Technology Ltd

Skillz Inc

<p>TD Cowen  analyst Joshua Buchalter   maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and lowers the price target from $35 to $32.</p>


Price Target

Analyst Ratings

ALGM

TD Cowen Maintains Buy on Allegro Microsystems, Lowers Price Target to $32

<p>Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.22, a high estimate of $32.00, and a low estimate of $3.00. Highlighting a 66.73% decrease, the current average has fallen from the previous average price target of $27.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364069_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Neena Bitritto-Garg</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amylyx Pharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Amylyx Pharma compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Amylyx Pharma's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Amylyx Pharma's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Amylyx Pharma analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Amylyx Pharma's Background</h2>
<p>Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.</p>
<h3>Financial Insights: Amylyx Pharma</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Amylyx Pharma's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>395.54%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Amylyx Pharma's net margin excels beyond industry benchmarks, reaching <strong>4.36%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Amylyx Pharma's ROE excels beyond industry benchmarks, reaching <strong>1.11%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Breaking Down Amylyx Pharma: 9 Analysts Share Their Views

<p>Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Equinix, revealing an average target of $862.42, a high estimate of $960.00, and a low estimate of $669.00. This upward trend is evident, with the current average reflecting a 3.02% increase from the previous average price target of $837.10.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364055_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Equinix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Elias</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$859.00</td>
<td>$862.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$669.00</td>
<td>$818.00</td>
</tr>
<tr>
<td>Simon Flannery</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$762.00</td>
<td>$767.00</td>
</tr>
<tr>
<td>Phani Kanumuri</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$900.00</td>
<td>-</td>
</tr>
<tr>
<td>Timothy Horan</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$875.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$950.00</td>
<td>$915.00</td>
</tr>
<tr>
<td>Erik Rasmussen</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$960.00</td>
<td>-</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$818.00</td>
<td>$781.00</td>
</tr>
<tr>
<td>Jonathan Atkin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$950.00</td>
<td>$855.00</td>
</tr>
<tr>
<td>Eric Luebchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$825.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Ari Klein</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$910.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$781.00</td>
<td>$788.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equinix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equinix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Equinix's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Equinix's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQIX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Equinix analyst ratings.</strong></a></p>
<h2>Delving into Equinix's Background</h2>
<p>Equinix operates 260 data centers in 71 markets worldwide. It generates 44% of total revenue in the Americas, 35% in Europe, the Middle East, and Africa, and 21% in Asia-Pacific. The firm has more than 10,000 customers, including 2,100 network providers, that are dispersed over five verticals: cloud and IT services, content providers, network and mobile services, financial services, and enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from interconnection. Equinix operates as a real estate investment trust.</p>
<h3>Equinix: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Equinix's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>12.81%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Equinix's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>10.78%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.87%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Equinix's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.71%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.4</strong>, Equinix adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EQIX

Breaking Down Equinix: 12 Analysts Share Their Views

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $14.1, a high estimate of $17.00, and a low estimate of $11.00. A decline of 11.88% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364044_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Bilibili. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Brian Gong</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.50</td>
<td>$18.00</td>
</tr>
<tr>
<td>Daniel Chen</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Fawne Jiang</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bilibili. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bilibili compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Bilibili's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Bilibili's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BILI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bilibili analyst ratings.</strong></a></p>
<h2>About Bilibili</h2>
<p>Bilibili is a Chinese online entertainment platform that is best known for its video-sharing site that resembles YouTube. The site was founded in 2009 and started as a long-form video platform for anime, comics, and gaming, or ACG, content that appealed to Gen Z users. Since then, it has expanded its content on the platform to include a broader range of interests that have attracted Chinese users outside of the Gen Z cohort. The firm generates revenue through five main areas: advertising, games, live streaming, value-added services, and e-commerce.</p>
<h3>Unraveling the Financial Story of Bilibili</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Bilibili showcased positive performance, achieving a revenue growth rate of <strong>3.36%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-20.42%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-8.69%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.87%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.53</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BILI

What Analysts Are Saying About Bilibili Stock

<p>Scotiabank  analyst Himanshu Gupta   upgrades Sienna Senior Living (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SIA#TSX">SIA</a>) from Sector Perform to Sector Outperform and raises the price target from C$14.5 to C$16.5.</p>


Upgrades

TSX:SIA

Scotiabank Upgrades Sienna Senior Living to Sector Outperform, Raises Price Target to C$16.5

<p>Ratings for Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Relay Therapeutics and provided 12-month price targets. The average target is $23.5, accompanied by a high estimate of $30.00 and a low estimate of $15.00. This current average represents a 3.41% decrease from the previous average price target of $24.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364032_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Relay Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Biegler</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Relay Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Relay Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Relay Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Relay Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RLAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Relay Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Relay Therapeutics</h2>
<p>Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).</p>
<h3>Relay Therapeutics: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Relay Therapeutics's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>4327.88%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-813.3%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-10.87%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-9.66%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Relay Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.07</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RLAY

Key Takeaways From Relay Therapeutics Analyst Ratings

<p>Across the recent three months, 5 analysts have shared their insights on Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Voya Financial and provided 12-month price targets. The average target is $85.4, accompanied by a high estimate of $92.00 and a low estimate of $78.00. Surpassing the previous average price target of $82.40, the current average has increased by 3.64%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364024_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Voya Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Voya Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Voya Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Voya Financial's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Voya Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VOYA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Voya Financial analyst ratings.</strong></a></p>
<h2>About Voya Financial</h2>
<p>Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.</p>
<h3>A Deep Dive into Voya Financial's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Voya Financial's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>10.48%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Voya Financial's net margin is impressive, surpassing industry averages. With a net margin of <strong>11.68%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Voya Financial's ROE excels beyond industry benchmarks, reaching <strong>5.61%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Voya Financial's ROA excels beyond industry benchmarks, reaching <strong>0.15%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Voya Financial's debt-to-equity ratio is below the industry average at <strong>0.84</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VOYA

The Analyst Verdict: Voya Financial In The Eyes Of 5 Experts

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Vacasa (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Vacasa, revealing an average target of $9.38, a high estimate of $10.00, and a low estimate of $8.00. Experiencing a 8.49% decline, the current average is now lower than the previous average price target of $10.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715364013_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Vacasa. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ben Miller</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.50</td>
<td>$11.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vacasa. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vacasa compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Vacasa's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vacasa's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VCSA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vacasa analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Vacasa</h2>
<p>Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.</p>
<h3>Vacasa: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Vacasa's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-18.66%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Vacasa's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-24.57%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vacasa's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-27.48%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Vacasa's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-6.1%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.2</strong>, Vacasa adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VCSA

Key Takeaways From Vacasa Analyst Ratings

<p>TD Cowen  analyst Gregory Williams   maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $84 to $78.</p>


CCOI

TD Cowen Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $78

<p>Former President <strong>Donald Trump</strong> is actively courting the cryptocurrency community, potentially becoming the first major party nominee to explicitly seek the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38765401/donald-trumps-crypto-endorsement-lauded-by-industry-figures-who-vow-to-support-president-t">support of digital asset traders</a>.</p>
<p><strong>What Happened</strong>: During a well-attended event at his Mar-a-Lago club, Trump made a direct appeal to crypto enthusiasts, urging them to vote for him due to the current administration&#8217;s stringent <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38736514/donald-trump-says-you-better-vote-for-him-if-youre-pro-crypto-but-has-he-always-been-fine-">regulatory stance on the industry.</a></p>
<p>&#8220;They are against it,&#8221; Trump declared, highlighting his commitment to fostering a more crypto-friendly environment in contrast to President Joe Biden&#8217;s approach, which includes aggressive enforcement actions by SEC Chair <strong>Gary Gensler</strong>. </p>
<p>This stance by the administration has frustrated crypto advocates, further intensified when the White House recently threatened to veto legislation aimed at rolling back SEC guidelines—a move that has not sat well with the industry.</p>
<p><strong>Kristin Smith</strong>, CEO of the Blockchain Association, <a href="https://www.politico.com/news/2024/05/10/trump-crypto-biden-00157051">noted</a>, &#8220;President Trump's remarks signal a sea change in the importance of digital assets this election cycle.&#8221; </p>
<p>This sentiment reflects a broader shift within the Republican Party, which has increasingly embraced bitcoin and other digital currencies, while Democrats remain divided, with figures like Senator <strong>Elizabeth Warren</strong> (D-Mass.) cautioning against the industry&#8217;s potential risks.</p>
<p>This emerging dynamic is setting the stage for digital assets to become a contentious issue in the upcoming elections. Trump&#8217;s alignment with crypto could indeed add a partisan tint to the ongoing debates over cryptocurrency regulation. </p>
<p>The industry, traditionally non-partisan in its lobbying efforts, now finds itself at a crossroads, needing to navigate these newly polarized waters.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure></p>
<p><em>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38765697/bitcoin-to-1-3m-by-2028-questionable-says-10x-research">Bitcoin To $1.3M By 2028? Questionable, Says 10x Research</a></em></p>
<p><strong>Why It Matters</strong>: Despite the potential electoral gains, the strategy of aligning closely with digital assets is not without its risks.</p>
<p>The crypto market is known for its volatility, and recent scandals, such as the collapse of the <strong>FTX </strong>exchange, have raised concerns about the industry&#8217;s stability and its susceptibility to fraud.</p>
<p>Ohio GOP Senate candidate <strong>Bernie Moreno</strong> praised Trump&#8217;s approach, stating, &#8220;President Trump understands freedom and liberty, he knows that innovation needs to be protected here in America.&#8221; </p>
<p>This endorsement reflects a growing sentiment among Republicans who view digital assets as a cornerstone of future financial innovation.</p>
<p>This issue presents an opportunity for bipartisan engagement and a reevaluation of the benefits and challenges associated with cryptocurrencies. </p>
<p>As <strong>Cody Carbone</strong>, chief policy officer at the Chamber of Digital Commerce, expressed, &#8220;I don't want this to become a partisan issue.&#8221; </p>
<p><strong>What&#8217;s Next</strong>: The importance of this issue is poised to be further explored at Benzinga's upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where leaders from across the industry will discuss the evolving relationship between cryptocurrency and mainstream politics.</p>
<p>This event will likely delve into how Trump's advocacy and the Democratic response could shape the<a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38739003/how-much-did-donald-trumps-crypto-portfolio-pump-after-he-said-hes-fine-with-it"> regulatory landscape moving forward.</a></p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38765130/fireblocks-global-custodian-partner-program-secure-digital-asset-custody-goes-global">Fireblocks Global Custodian Partner Program: Secure Digital Asset Custody Goes Global</a></em></p>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Decoding Donald Trump's Crypto Gambit

<p>TD Cowen  analyst Shaul Eyal   maintains Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) with a Buy and lowers the price target from $7 to $6.</p>


EVLV

TD Cowen Maintains Buy on Evolv Technologies, Lowers Price Target to $6

Tech

Alphabet Shares Move Higher After Sam Altman Says May 13 ChatGPT Demo Will Not Include Search Engine

<p>Scotiabank  analyst Michael Doumet   maintains Savaria (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SIS#TSX">SIS</a>) with a Sector Outperform and raises the price target from C$21.5 to C$22.</p>


TSX:SIS

Scotiabank Maintains Sector Outperform on Savaria, Raises Price Target to C$22

<p>TD Cowen  analyst Michael Elias   maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Buy and lowers the price target from $862 to $859.</p>


TD Cowen Maintains Buy on Equinix, Lowers Price Target to $859

<p><a href="https://twitter.com/sama/status/1788989777452408943" title="https://twitter.com/sama/status/1788989777452408943">https://twitter.com/sama/status/1788989777452408943</a></p>


MSFT

Sam Altman On X Posts "not gpt-5, not a search engine, but we've been hard at work on some new stuff we think people will love!"

<p>High-rolling investors have positioned themselves bullish on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in HUM often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Humana. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 50% bullish and 25% bearish. Among all the options we identified, there was one put, amounting to $40,080, and 7 calls, totaling $265,127.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $340.0 for Humana over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $300.0 to $340.0 over the preceding 30 days.</p>
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715363551_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$63.1</td>
<td>$57.1</td>
<td>$60.0</td>
<td>$300.00</td>
<td>$60.0K</td>
<td>97</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$17.5</td>
<td>$15.7</td>
<td>$16.79</td>
<td>$320.00</td>
<td>$58.8K</td>
<td>1.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/31/24</td>
<td>$5.4</td>
<td>$4.9</td>
<td>$5.01</td>
<td>$330.00</td>
<td>$40.0K</td>
<td>41</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$66.0</td>
<td>$64.5</td>
<td>$66.0</td>
<td>$310.00</td>
<td>$33.0K</td>
<td>12</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$36.5</td>
<td>$36.1</td>
<td>$36.5</td>
<td>$305.00</td>
<td>$32.8K</td>
<td>123</td>
<td style="text-align: right;">9</td>
</tr>
</tbody>
</table>
</p>
<h3>About Humana</h3>
<p>Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.</p>
<p>Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Humana</h3>
<ul>
<li>With a trading volume of 704,174, the price of HUM is up by 0.85%, reaching $337.51.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $358.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Neutral rating for Humana, targeting a price of $360. </li>
<li>An analyst from UBS has decided to maintain their Neutral rating on Humana, which currently sits at a price target of $326. </li>
<li>An analyst from RBC Capital persists with their Outperform rating on Humana, maintaining a target price of $353. </li>
<li>Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Humana, targeting a price of $381. </li>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Humana with a target price of $370. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Humana Options Trading: A Deep Dive into Market Sentiment

<p>Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 55% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $72,059, and 7 were calls, valued at $273,450.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $70.0 for Gilead Sciences during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $60.0 to $70.0, over the past month.</p>
<h3>Gilead Sciences Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715363545_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.35</td>
<td>$67.50</td>
<td>$93.5K</td>
<td>534</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.7</td>
<td>$3.65</td>
<td>$3.7</td>
<td>$65.00</td>
<td>$37.0K</td>
<td>1.3K</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.75</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$65.00</td>
<td>$35.0K</td>
<td>1.3K</td>
<td style="text-align: right;">305</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.3</td>
<td>$65.00</td>
<td>$33.9K</td>
<td>2.0K</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.2</td>
<td>$6.0</td>
<td>$6.18</td>
<td>$60.00</td>
<td>$30.9K</td>
<td>89</td>
<td style="text-align: right;">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Gilead Sciences</h3>
<p>Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.</p>
<p>After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 5,292,112, the GILD's price is up by 2.29%, now at $66.06. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Gilead Sciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


GILD

Decoding Gilead Sciences's Options Activity: What's the Big Picture?

<p>Financial giants have made a conspicuous bearish move on Workday. Our analysis of options history for Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $139,576, and 6 were calls, valued at $1,146,186.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $290.0 for Workday, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Workday's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Workday's significant trades, within a strike price range of $240.0 to $290.0, over the past month.</p>
<h3>Workday Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715363540_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$25.2</td>
<td>$25.1</td>
<td>$25.1</td>
<td>$290.00</td>
<td>$529.6K</td>
<td style="text-align: right;">422</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/10/24</td>
<td>$0.9</td>
<td>$0.55</td>
<td>$0.71</td>
<td>$247.50</td>
<td>$375.0K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$26.6</td>
<td>$25.7</td>
<td>$26.3</td>
<td>$240.00</td>
<td>$92.0K</td>
<td style="text-align: right;">21</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>WDAY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$260.00</td>
<td>$71.0K</td>
<td style="text-align: right;">373</td>
<td style="text-align: right;">143</td>
</tr>
<tr>
<td>WDAY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$36.1</td>
<td>$35.7</td>
<td>$36.0</td>
<td>$270.00</td>
<td>$54.0K</td>
<td style="text-align: right;">393</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Workday</h3>
<p>Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 18,000 employees.</p>
<p>After a thorough review of the options trading surrounding Workday, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Workday Standing Right Now?</h3>
<ul>
<li>With a trading volume of 668,159, the price of WDAY is up by 0.29%, reaching $246.68.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Workday with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


WDAY

Market Whales and Their Recent Bets on WDAY Options

<p><strong>Needham</strong>&nbsp;analyst Chris Pierce cut the price target of&nbsp;<strong>Blink Charging Co.&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from $7 to $6 while retaining the Buy rating following the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/BLNK/analyst-ratings" rel="noreferrer noopener">first quarter earnings release</a>.</p>
<p>Yesterday, Blink Charging reported quarterly adjusted losses of 13 cents per share&nbsp;which&nbsp;beat the analyst consensus estimate of losses of 24 cents. Quarterly sales of $37.57 million beat the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38744873/blink-charging-stock-climbs-after-better-than-expected-q1-results" rel="noreferrer noopener">consensus estimate of $33.38 million</a>.</p>
<p>Blink maintained its&nbsp;target of revenues&nbsp;between $165 million and $175 million and reiterated its target of achieving a positive adjusted EBITDA&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">run rate by December 2024</a>.</p>
<p>The analyst sees the company as the best-positioned&nbsp;as&nbsp;the&nbsp;EV&nbsp;charging business with conservative FY24 gross margin guidance vs first quarter results and levers to pull as they restructure their lines of business and trim operating expenses.</p>
<p>Also, Pierce highlights that&nbsp;<strong>Tesla, Inc.</strong>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/05/38541246/tesla-ceo-elon-musk-says-supercharger-network-will-still-grow-but-at-a-slower-pace-for-new-locations" rel="noreferrer noopener">news provides upside opportunities</a>. Consequently, the&nbsp;analyst sees Blink as well positioned to win any North American Level 2 business thanks to their vertical integration and Level 2 industry leader&nbsp;<strong>ChargePoint Holdings, Inc.</strong>&#8216;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) recent comments that large customers are now opting for multi-sourcing charging hardware.</p>
<p>However, the analyst writes that Blink cited a slowing of bookings vs their expectations in April, with slowing EV adoption and weak demand for EV charging equipment.</p>
<p>The analyst cut&nbsp;FY24&nbsp;revenue estimate to $164.8 million from $169.7 million.</p>
<p>Apart from this,&nbsp;<strong>B. Riley&nbsp;Securities</strong>&nbsp;analyst Christopher Souther maintained a&nbsp;Neutral rating with a price target of $3.00.</p>
<p>The analyst remains cautiously optimistic and sees growth, operating expenses, and margin execution as&nbsp;key&nbsp;drivers for achieving positive EBITDA.</p>
<p><strong>Price Action</strong>: BLNK shares are up 2.46% at $2.9100 at the last check Friday.</p>
<p><em>Photo vis Shutterstoc</em>k</p>


Analyst Color

Earnings

Reiteration

BLNK

CHPT

Blink Charging Has Upside Potential Despite Slowed Bookings: Analyst

<p><a href="https://openai.com/" title="https://openai.com/">https://openai.com/</a></p>


OpenAi Announces Live Stream At 10 A.M. PT On May 13 To Demo ChatGPT And GPT-4 Updates

Skillsoft (SKIL) has provided an update. Skillsoft Corp. recently updated investors with an earnings supplement presentation on their website, prov...

Skillsoft Shares Financial Insights in Earnings Update

Skillsoft Corp. 2024 Q4 - Results - Earnings Call Presentation

Skillsoft Corp. (SKIL) Q4 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Skillsoft</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/skil-stock-quote/"><strong>SKIL</strong></a></span>) just reported results for the fourth quarter of 2024.</p><ul><li>Skillsoft reported earnings per share of -$3.09. This was above the analyst estimate for EPS of -$3.27.</li><li>The company reported revenue of $137.54 million.</li><li>This was 3.07% worse than the analyst estimate for revenue of $141.90 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/skil-stock-earnings-skillsoft-for-q4-of-2024/">SKIL Stock Earnings: Skillsoft Beats EPS, Misses Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SKIL Stock Earnings: Skillsoft Beats EPS, Misses Revenue for Q4 2024

Raimo Lenschow, an analyst from Barclays, maintained the Buy rating on Skillsoft (SKIL – Research Report). The associated price target was lowered ...

Maintaining Buy Rating on Skillsoft Amid Turnaround Potential and Solid Customer Base

Analysts have been eager to weigh in on the Technology sector with new ratings on Skillsoft (SKIL – Research Report) and T Stamp, Inc. Class A (IDA...

Analysts Offer Insights on Technology Companies: Skillsoft (SKIL) and T Stamp, Inc. Class A (IDAI)

Better Choice, Kaival Brands among Consumer Staples movers

JAGX, BSGM and SXTC among mid-day movers

Skillsoft Corp (SKIL) has disclosed a new risk, in the Regulation category. Skillsoft Corp faces potential disruption due to changing legislative l...

Regulatory Roulette: How AI Legislation Could Reshape Skillsoft's Financial Future

BOF, SKIL among Consumer Staples movers

AUUD

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Skillsoft Stock (NYSE:SKIL), Short Interest Report

People Also Watch